Literature DB >> 16417950

Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine.

S F Little1, B E Ivins, W M Webster, P F Fellows, M L M Pitt, S L W Norris, G P Andrews.   

Abstract

Long-term protection of rabbits that had been vaccinated with two doses of a recombinant protective antigen (rPA) vaccine was examined against an aerosol spore challenge with the Ames isolate of Bacillus anthracis at 6 and 12 months. At 6 months after the primary injection, survival was 74.1% (20/27) with quantitative ELISA titer of 22.3 microg of anti-rPA IgG per millilitre and toxin neutralizing antibody (TNA) assay titer of 332. At 12 months after the primary injection, only 37.5% (9/24) of the rabbits were protected with quantitative ELISA titer of 19.8 microg of anti-rPA IgG per millilitre and TNA assay titer of 286. There was a significant loss of protection (p = 0.0117) and a significant difference in survival curves (p = 0.0157) between the 6- and 12-month groups. When ELISA or TNA assay titer, gender, and challenge dose were entered into a forward logistic regression model, week 26 ELISA titer (p = 0.0236) and week 13 TNA assay titer (p = 0.0147) for the 6-month group, and week 26 ELISA titer (p = 0.0326) and week 8 TNA assay titer (p = 0.0190) for the 12-month group, were significant predictors of survival. Neither gender nor challenge dose were identified as having a statistically significant effect on survival. Booster vaccinations with rPA may be required for the long-term protection of rabbits against anthrax.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16417950     DOI: 10.1016/j.vaccine.2005.12.028

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

1.  Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.

Authors:  Vladimir Savransky; Jeffry D Shearer; Melicia R Gainey; Daniel C Sanford; Gloria S Sivko; Gregory V Stark; Na Li; Boris Ionin; Michael J Lacy; Mario H Skiadopoulos
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

2.  Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.

Authors:  Boris Ionin; Robert J Hopkins; Brett Pleune; Gloria S Sivko; Frances M Reid; Kristin H Clement; Thomas L Rudge; Gregory V Stark; Alison Innes; Suha Sari; Tina Guina; Cris Howard; Jeffrey Smith; M Lisa Swoboda; Ekaterina Vert-Wong; Virginia Johnson; Gary S Nabors; Mario H Skiadopoulos
Journal:  Clin Vaccine Immunol       Date:  2013-05-08

3.  Epitope-focused peptide immunogens in human use adjuvants protect rabbits from experimental inhalation anthrax.

Authors:  Jon Oscherwitz; Daniel Feldman; Fen Yu; Kemp B Cease
Journal:  Vaccine       Date:  2014-11-30       Impact factor: 3.641

4.  A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.

Authors:  Conrad P Quinn; Carol L Sabourin; Nancy A Niemuth; Han Li; Vera A Semenova; Thomas L Rudge; Heather J Mayfield; Jarad Schiffer; Robert S Mittler; Chris C Ibegbu; Jens Wrammert; Rafi Ahmed; April M Brys; Robert E Hunt; Denyse Levesque; James E Estep; Roy E Barnewall; David M Robinson; Brian D Plikaytis; Nina Marano
Journal:  Clin Vaccine Immunol       Date:  2012-08-29

Review 5.  The Bacillus cereus Group: Bacillus Species with Pathogenic Potential.

Authors:  Monika Ehling-Schulz; Didier Lereclus; Theresa M Koehler
Journal:  Microbiol Spectr       Date:  2019-05

6.  Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine.

Authors:  John A Mikszta; John P Dekker; Noel G Harvey; Cheryl H Dean; John M Brittingham; Joanne Huang; Vincent J Sullivan; Beverly Dyas; Chad J Roy; Robert G Ulrich
Journal:  Infect Immun       Date:  2006-10-09       Impact factor: 3.441

7.  Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant.

Authors:  Brandon Feinen; Nikolai Petrovsky; Anita Verma; Tod J Merkel
Journal:  Clin Vaccine Immunol       Date:  2014-02-19

8.  Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model.

Authors:  Johnny W Peterson; Jason E Comer; Wallace B Baze; David M Noffsinger; Autumn Wenglikowski; Kristin G Walberg; Jason Hardcastle; Jennifer Pawlik; Kathryn Bush; Joanna Taormina; Scott Moen; John Thomas; Bagram M Chatuev; Laurie Sower; Ashok K Chopra; Lawrence R Stanberry; Ritsuko Sawada; Wolfgang W Scholz; Jagadish Sircar
Journal:  Infect Immun       Date:  2007-04-23       Impact factor: 3.441

9.  The physiologic responses of Dutch belted rabbits infected with inhalational anthrax.

Authors:  William S Lawrence; Jason M Hardcastle; Douglas L Brining; Lori E Weaver; Cindy Ponce; Elbert B Whorton; Johnny W Peterson
Journal:  Comp Med       Date:  2009-06       Impact factor: 0.982

10.  A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge.

Authors:  S D Klas; C R Petrie; S J Warwood; M S Williams; C L Olds; J P Stenz; A M Cheff; M Hinchcliffe; C Richardson; S Wimer
Journal:  Vaccine       Date:  2008-08-12       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.